Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s Disease

12 Feb 2020

Abstract excerpt

The search for new disease-modifying drugs for Parkinson’s disease is a slow and highly expensive process, and the repurposing of drugs already approved for different medical indications is becoming a compelling alternative option for researchers. Genetic variables represent a predisposing factor to the disease and mutations in Leucine-rich repeat kinase 2 (LRRK2) locus have been correlated to late-onset...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Insect Resistance and Genetics
Share to Neurobiology and Insect Physiology Research
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32116655
DOI: 10.3389/fnagi.2020.00031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinson’s DiseasePMID 32116655Read ↗

Neuroprotective Effects of the Nutraceutical Dehydrozingerone and Its C2-Symmetric Dimer in a Drosophila Model of Parkinson's Disease.Semantic proximity Read ↗

Neuroprotective Effects of the Nutraceutical Dehydrozingerone and its C2- symmetric Dimer in a Drosophila Model of Parkinson’s DiseaseSemantic proximity Read ↗

Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s diseaseSemantic proximity Read ↗

Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.Semantic proximity Read ↗

Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models.Semantic proximity Read ↗

Rosiglitazone alleviates Parkinson's disease phenotypes of Drosophila via dCTP-mediated inhibition of AGE-RAGE pathway.Semantic proximity Read ↗

Identification of structural features of selected flavonoids responsible for neuroprotection using a <i>Drosophila</i> model of Parkinson’s diseaseSemantic proximity Read ↗

Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson’s disease mutant of Leucine-rich repeat kinase 2 (LRRK2)Semantic proximity Read ↗

Integration of National Health Insurance Claim Data and Animal Models Reveals Fexofenadine as a Promising Repurposed Drug for Parkinson’s DiseaseSemantic proximity Read ↗

Folic Acid Supplementation Ameliorates Oxidative Stress, Metabolic Functions and Developmental Anomalies in a Novel Fly Model of Parkinson’s DiseaseSemantic proximity Read ↗

A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1.Semantic proximity Read ↗

Drug screens of NGLY1 Deficiency worm and fly models reveal catecholamine, NRF2 and anti-inflammatory pathway activation as clinical approachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.